Aug 2026· Frontiers in Immunology· Vol 17· 0 citations· 113 references
Medicine
TL;DR
This review summarizes recent advances in molecular imaging techniques for monitoring the in vivo fate of CAR-T cells, covering their dynamic distribution, tumor recognition, and real-time functional activity and proposes an interdisciplinary integration of these approaches.
Abstract
Despite the remarkable therapeutic efficacy of chimeric antigen receptor T (CAR-T) cell therapy in hematologic malignancies, its clinical translation in solid tumors remains impeded by challenges including insufficient intratumoral infiltration, tumor heterogeneity, and the immunosuppressive tumor microenvironment. Molecular imaging, which enables the visualization and quantitative analysis of the in vivo behavior of CAR-T cells, serves as a critical prerequisite for advancing the clinical application of CAR-T cell therapy in solid tumors. This review summarizes recent advances in molecular imaging techniques for monitoring the in vivo fate of CAR-T cells, covering their dynamic distribution, tumor recognition, and real-time functional activity. Additionally, the potential clinical value and current limitations of these approaches are discussed. It is proposed that this interdisciplinary integration may improve the precision of therapeutic response assessment and facilitate the optimization of personalized treatment strategies in the context of CAR-T cell therapy.
The major obstacles limiting CAR-T therapy in GBM are summarized and emerging strategies to overcome these challenges are discussed, paving the way for future CAR-T-based therapies in glioblastoma.
Lin Chen, Z. Zou· Critical reviews in oncology...· 0 citations
This review comprehensively examines the current landscape of CAR-T cell therapy for colon cancer, focusing on its underlying mechanisms, recent clinical advances, major challenges, and future perspectives.
Arifa Raza, M. Raza, Junaid Khan et al.· Pathology, Research and Prac...· 0 citations
Although still in its infancy, in vivo genetic engineering shows promise for CAR T cell therapy in a wide range of cancer patients and has the potential to reprogram patients’ immunity in autoimmunity, chronic infections, and regenerative medicine.
Markus Barden, D. Harrer, Hinrich Abken· Expert Opinion on Biological...· 0 citations
It is argued that the major limitations of CAR-T therapy in solid tumors arise from a complex interplay between biological barriers and engineering constraints, and future advances will likely depend less on improving gene delivery and more on establishing mechanisms that support CAR-T infiltration, expansion, and pers...
This review article focuses on CAR-T cell bioengineering, antitumor mechanism of action, challenges and limitations, as well as the latest innovative nanotechnological solutions for complementing CAR-T cell immunotherapy.
Alaa Ibrahim, Maha Nasr· Biochimica et biophysica act...· 1 citation
Current challenges in solid tumour treatment are examined through evidence from clinical trials, highlighting key obstacles such as antigen heterogeneity, the immunosuppressive tumour microenvironment, poor cellular trafficking, and treatment-related failures that have informed the development of next-generation CAR co...
A. Justiz-Vaillant, Sachin Soodeen, Rodolfo Arozarena-Fundora et al.· Frontiers in Molecular Medic...· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.